Advertisement Ligand earns milestone payment triggered by EU approval of Merck’s captisol-enabled NOXAFIL - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Ligand earns milestone payment triggered by EU approval of Merck’s captisol-enabled NOXAFIL

Ligand Pharmaceuticals Incorporated (LGND) has announced that Merck, known as MSD outside the United States and Canada, has received approval for NOXAFIL (posaconazole) 300 mg Concentrate for Solution for Infusion from the European Medicines Agency (EMA).

Ligand earns a $550,000 milestone payment as a result of the approval. Ligand will sell Captisol to Merck for the product marketed in Europe under an existing commercial supply agreement.

The EMA approval grants Merck centralized marketing authorization with unified labeling that is valid in the 28 countries that are members of the European Union, as well as European Economic Area members, Iceland, Liechtenstein and Norway.

NOXAFIL is a novel triazole antifungal agent with demonstrated broad-spectrum activity, covering both yeast and molds responsible for serious invasive fungal infections.

The availability of a NOXAFIL formulation for intravenous administration is particularly important for those patients who may benefit from or require intravenous therapy, or who might not be able to take an oral formulation. Merck also markets oral suspension and tablet formulations of NOXAFIL.

Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella at the University of Kansas’ Higuchi Biosciences Center for specific use in drug development and formulation.

This unique technology has enabled six FDA-approved products, including Onyx Pharmaceuticals’ Kyprolis, Baxter International’s Nexterone and Merck’s Noxafil IV. There are currently more than 50 Captisol-enabled products in development, including Lundbeck’s Carbella, Spectrum Pharmaceuticals’ Captisol-enabled Melphalan and Melinta Therapeutics’ delafloxacin IV program.